Compounded Semaglutide vs. Ozempic: What to Ask Before You Start

I've spent enough of my own weight-care journey reading fine print to know how tempting it is to let a familiar ingredient name stand in for a real answer. As a physician navigating my own struggles with this process, I care about whether an option is actually understandable and manageable, not just whether it sounds close enough to something FDA-approved.

Quick answer: A compounded semaglutide preparation is not the FDA-approved Ozempic product. Compounding can serve real clinical needs, but approval status, formulation, preparation, instructions, and applicable rules all matter. Supporting responsible access doesn't require calling different products interchangeable.

I support responsible compounding. I also think people deserve a better explanation than either "it's exactly the same" or a frightening headline that treats every compounded medicine as identical to the last one you heard about.

What does the FDA's current explanation say?

The FDA's guidance on unapproved GLP-1 drugs draws a clear distinction between approved products and compounded preparations:

• Compounded drugs don't undergo the FDA's premarket review for safety, effectiveness, and quality.
• The agency has identified specific problems, including fraudulent labels, dosing errors, and improper shipping conditions.

That guidance is useful because it names concrete risks. Its limits matter too: it isn't an assessment of your specific prescription, your pharmacy, or every preparation that exists. A reader should leave with specific questions to ask, not a blanket endorsement or a blanket dismissal. Neither one actually helps you.

What does "the same active ingredient" leave unanswered?

Even when a preparation uses semaglutide, the ingredient name alone doesn't answer:

• Whether it's an FDA-approved finished product.
• How it was actually prepared.
• What instructions apply to that specific container.

Ozempic and Wegovy are also distinct branded products with their own labeling and indications. A brand name isn't simply a casual synonym for anything containing semaglutide. The FDA also distinguishes semaglutide sodium and acetate from the ingredient used in approved drugs, so don't assume a salt form is automatically interchangeable.

The question worth asking is: "What exactly am I being prescribed and dispensed?" The answer should identify the medicine, the formulation, the dispensing pharmacy, and the product-specific directions. That's a basic expectation of clarity, especially when marketing has made different options sound identical.

Is compounding still permitted after the shortage changes?

The rules are conditional, and they've shifted. In its most recent update, the FDA describes:

• Restrictions on routinely compounding essentially copies of commercially available drugs under section 503A.
• An exception for a prescriber-documented change that produces a significant difference for an identified patient.
• Separate requirements under section 503B.

The same update notes that semaglutide and tirzepatide are not on the relevant shortage or 503B bulk-ingredient lists at this time. Adding another ingredient doesn't automatically resolve the "essentially a copy" question. That's why I wouldn't decide legality from a single phrase on a sales page. The specific prescription, preparation, pharmacy category, and current rules all matter, and this article isn't a legal determination about any individual product. A clinician and pharmacy should be able to explain the clinical rationale and the applicable pathway. Affordability matters deeply, but a lower price alone doesn't answer those questions.

Why do vial instructions deserve their own conversation?

A dosing instruction is only useful if you actually understand which medicine and concentration it refers to. There have been reported errors involving compounded injectable semaglutide, including confusion between milligrams, milliliters, and syringe "units," with some cases severe enough to require hospitalization.

I'd want the prescriber or pharmacist to walk through the instructions using the actual dispensed product and device, not a generic chart. Ask for clarification if the label, the written directions, and the verbal explanation don't match each other. Don't use another person's syringe chart. A shared ingredient name isn't enough to establish that another vial's concentration or directions apply to yours.

What should you ask about the pharmacy and shipping?

Use specific questions rather than relying on a badge or testimonial on a website:

• Who is dispensing this? The actual pharmacy, and how to contact it.
• What am I receiving? Ingredient, formulation, concentration, and container.
• Why this preparation? The patient-specific clinical rationale.
• How do I use it? Directions for this exact prescription and device.
• How is it stored? Product-specific storage and handling instructions.
• What if the package looks wrong? Who to contact before you use it.
• What happens after a problem? The clinical follow-up and reporting route.

Injectable GLP-1 products that arrive warm or without adequate refrigeration are a known concern. If a shipment arrives that way, don't use it; contact the dispensing pharmacy and prescriber about next steps instead.

What does responsible support for compounding actually look like?

It means being willing to explain both the opportunity and the limits. I want people to understand why a compounded option is being considered, what evidence can and can't be carried over from branded products, and what support exists if treatment becomes difficult to manage.

I also want room for a different answer for a different person. An approved product may be appropriate and accessible for one person. Someone else's clinical circumstances may warrant a different discussion entirely. The quality of that discussion should matter more than which option a business happens to prefer selling. A useful consultation should be able to say both "here's why this option fits" and "here's what would make us reconsider it."

If you're weighing this decision, you can explore Body Good's approach to weight care and bring the questions above into that conversation. The right decision starts with your actual circumstances, not a headline.

How can you compare the financial side without losing the clinical context?

Ask for a written description of medication charges, care charges, refill arrangements, and any recurring fee, then compare those alongside the product and follow-up details, not on their own. If insurance coverage could change your options, start with Body Good's free preliminary commercial-insurance check. It provides a preliminary estimate, not insurer-verified benefits or a guaranteed approval.